Optum, a subsidiary of UnitedHealth Group, has submitted an all-cash proposal to the Board of Directors of Amedisys in a bid to combine with the home health, hospice and high-acuity care provider in a transaction estimated at $3.26 billion.

The $100 per share all-cash transaction represents a 26% premium over Amedisys’ most recent closing share price and a premium of 29% to the unaffected Amedisys share price of $77.26. 

Skip to content